Analytical Evidence Report

HPLC-UV results for the submitted Tesamorelin sample

REPORT NUMBER
CBI-TESA-10-091826

GENERATED
September 25, 2026

Tesamorelin

Results and chromatograms

Sample vial 13, injection 1 | Client report CBI-TESA-10-091826

Laboratory Analysis: LAB-CA-02

Laboratory identity and applicable credentials are maintained by Testides and are available to regulatory authorities where required by law.

VIAL PHOTOGRAPH	SAMPLE INFORMATION		ANALYSIS		RUN DETAILS	
	Peptide:	**Tesamorelin**	Method:	**HPLC-UV**	Run date:	**Sep 24, 2026**
	Client ID:	**CBI-TESA-10-091826**	Channel:	**214 nm**	Acquired:	**02:30:46 UTC**
	Label claim:	**10 mg**	Integration:	**Laboratory**	Run time:	**35 min**
	Injection:	**10 uL, 214 nm**	Identity:	**Lab-assigned peak**	Instrument:	**HPLC 01**

RESULTS AT A GLANCE

PROJECTED AMOUNT	HPLC PURITY	CONTENT VS. LABEL	IDENTITY
10.30 mg*	**93.18%**	**103.0%**	**Assigned**
EXTRAPOLATED; OUTSIDE CURVE	214 NM AREA PERCENT*	10.30 MG OF 10 MG CLAIMED	LAB-ASSIGNED PEAK + RETENTION**

CHROMATOGRAM

As integrated by the laboratory - every plotted reading, with its baselines and peak marks



HPLC PURITY (214 NM)

Main peak area %	Integrated peaks	Smallest peak integrated	Recovered chromatogram
93.18%	**3**	**0.26%**	**±0.01%**
Laboratory integration	Counted in the total	Of total area	Area vs. laboratory table

Purity is the laboratory-assigned peak's share of the total peak area the laboratory integrated at 214 nm. The smallest peak it integrated was 0.26% of the total; the laboratory does not state a reporting threshold, so peaks below the ones it integrated are not counted. Integrating the chromatogram recovered from the laboratory's report reproduces its main-peak area to within 0.01%. This result rests on a single injection.

The chromatogram is recovered point for point from the laboratory's report: 241 plotted readings from 17.00 to 21.00 min, joined as drawn; nothing is smoothed or resampled.

* HPLC purity is the laboratory-assigned peak's share of all peak area the laboratory integrated; every peak is itemised on page 3.

** Identity: the laboratory's processing method names the analyte's peak, and its retention time is within ±5% of the laboratory's reference standard on the same method (-0.28%).

Tesamorelin

Sample vial 13, injection 1 | Client report CBI-TESA-10-091826

Reference comparison and calculation

CONCENTRATION CALIBRATION - 214 NM (LABORATORY VALIDATION CURVE)



mg/mL	Area (uV*s)	Recovery
0.5	2,382,396	100.13%
0.25	1,138,337	99.22%
0.1	419,345	102.05%
0.05	159,374	98.53%

Area = 4,924,969 C -83,255
Unweighted OLS through 4 levels | R2 0.99993
Sample area 2,453,023 = 0.5150 mg/mL (label: 0.5) * outside curve
x 2 mL x 10 = 10.30 mg

† 2 mL diluent, diluted x10 to the working 0.5 mg/mL

Validated 2026-09-08 | HPLC 01 | injector RSD 0.71% (n=6) | reference 99.1% pure

MAIN PEAK COMPARED WITH THE LABORATORY'S REFERENCE STANDARD





Native plotted readings with the laboratory's integration baselines and peak marks; nothing is smoothed or resampled.
Reference standard injected 2026-09-04 during the laboratory's validation of this curve; same instrument method as the sample (retention -0.28%).

Understanding Your Report

What the measurements mean and how to read the supporting detail

Tesamorelin

Definitions, calculation detail, and scope

Sample vial 13, injection 1 | Client report CBI-TESA-10-091826

HOW TO READ THIS REPORT

Start with the result on page 1. Pages 2 and 3 show the curve, comparison, and peaks behind it.

01 **Recovered chromatogram**
The laboratory's trace, read back point for point from its report.

02 **Integrated peak table**
Every peak the laboratory integrated, and which one is the analyte.

03 **Validation curve**
Converts the peak area to a concentration for this analyte.

WHAT THE RECOVERED CHROMATOGRAM ADDS

How the chromatogram on this report was obtained

How it was recovered

The laboratory's data system draws the chromatogram in its report as vector data. Every vertex it drew was read back - 241 readings - and both axes were calibrated from the report's own tick marks. Integrating the recovered trace over the laboratory's baselines and peak marks reproduces the area in its peak table to within 0.01%.

What it can and cannot show

It shows every peak, shoulder and baseline the laboratory integrated, at the resolution the laboratory printed. It carries a single wavelength and no UV spectrum, so it cannot reveal a co-eluting compound the way diode-array data can.

Scope: the recovered chromatogram reproduces the laboratory's report. It does not re-measure the sample.

HOW THE PURITY RESULT WAS MEASURED

214 nm area percent, from the laboratory's own integration

The laboratory integrated each peak to its own baseline and named the analyte's peak in its processing method. Purity is that peak's share of the total integrated area; the shares below are recomputed from the areas, and each peak's area is checked against the recovered chromatogram.

Purity (%) = assigned peak area / total integrated peak area x 100

Peak	RT (min)	Area (uV*s)	Area %	Tailing	Plates	Role	Recovered
1	18.077	172,678	6.56	1.04	166,747	impurity	-
2	18.355	6,836	0.26	0.96	233,426	impurity	-
3	**18.590**	**2,453,023**	**93.18**	**1.17**	**191,539**	**Peak#1 - main**	**2,452,899 (-0.01%)**

Integrated peaks 3 | smallest 0.26% of total | injections 1

Area percent assumes every peak absorbs at 214 nm like the main peak; the analyte's peak is the one the laboratory's method names. Recovered areas are compared for the analyte's peaks of 1% or more.

WHAT THIS REPORT CAN AND CANNOT TELL YOU

The report explains the measurement; it does not decide how a material should be used

Observed evidence
The laboratory's chromatogram, its integration, and its validation curve.

Identity and composition
No definitive identity or absolute purity unless separately supported.

Calculated results
Area-percent purity, concentration, projected amount, and calibration trace.

Safety and performance
No conclusion on safety, sterility, efficacy, fitness for purpose, or suitability.

Method context
Laboratory peak assignment; retention against its reference standard where methods match.

Regulatory status
No regulatory compliance finding, approval, or authorization to manufacture, sell, or use.

This analytical record does not authorize or endorse manufacture, sale, marketing, distribution, or use of the material.